RecruitingPhase 2NCT07084012

A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS

Studying Androgen insensitivity syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shenzhen Wingor Biotechnology Co., Ltd.
Intervention
hUC-MSCs treatment (high dose)(drug)
Enrollment
60 target
Eligibility
18-75 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

Beijing Tiantan Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07084012 on ClinicalTrials.gov

Other trials for Androgen insensitivity syndrome

Additional recruiting or active studies for the same condition.

See all trials for Androgen insensitivity syndrome

← Back to all trials